News | August 27, 2021
Marksans announces US FDA approval for Acetaminophen Extended- Release tablets
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
In 2018 NATCO and Alvogen had filed an Abbreviated New Drug Application (ANDA) with PIV certification for the generic version of the product
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
It’s an AB-rated generic therapeutic version of Durezol
It had an estimated market size of US $ 32 million as of June 2021
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
Subscribe To Our Newsletter & Stay Updated
